Back to Research Hub
Immunocore Holdings plc
IMCR
$28.52+0.73 (+2.63%)
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma.
StreetsValue research for Immunocore Holdings plc (IMCR)
Members get the full report for Immunocore Holdings plc: a fair value estimate and valuation analysis, economic moat rating, growth and profitability factor grades, a bull and bear investment thesis, analyst price targets, insider and congressional trading activity, and which super investors own the stock.